Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum.

Harvey PD, Cosentino S, Curiel R, Goldberg TE, Kaye J, Loewenstein D, Marson D, Salmon D, Wesnes K, Posner H.

Innov Clin Neurosci. 2017 Feb 1;14(1-2):30-39. eCollection 2017 Jan-Feb. Review.

2.

Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs.

Posner H, Curiel R, Edgar C, Hendrix S, Liu E, Loewenstein DA, Morrison G, Shinobu L, Wesnes K, Harvey PD.

Innov Clin Neurosci. 2017 Feb 1;14(1-2):22-29. eCollection 2017 Jan-Feb.

3.

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic.

O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H; Biofluid Based Biomarker Professional Interest Area.

Alzheimers Dement. 2017 Jan;13(1):45-58. doi: 10.1016/j.jalz.2016.09.014. Epub 2016 Nov 18.

4.

Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes.

French J, Glue P, Friedman D, Almas M, Yardi N, Knapp L, Pitman V, Posner HB.

Neurology. 2016 Sep 20;87(12):1242-9. doi: 10.1212/WNL.0000000000003118. Epub 2016 Aug 12.

5.

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Foroud T, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R; STAR-B and BBBIG working groups.

Alzheimers Dement. 2015 May;11(5):549-60. doi: 10.1016/j.jalz.2014.08.099. Epub 2014 Oct 1. Review.

6.

Adjunctive use of controlled-release pregabalin in adults with treatment-resistant partial seizures: a double-blind, randomized, placebo-controlled trial.

French J, Brandt C, Friedman D, Biton V, Knapp L, Pitman V, Chew M, Dubrava S, Posner HB.

Epilepsia. 2014 Aug;55(8):1220-8. doi: 10.1111/epi.12690. Epub 2014 Jun 24.

7.

Efficacy and safety of pregabalin versus levetiracetam as adjunctive therapy in patients with partial seizures: a randomized, double-blind, noninferiority trial.

Zaccara G, Almas M, Pitman V, Knapp L, Posner H.

Epilepsia. 2014 Jul;55(7):1048-57. doi: 10.1111/epi.12679. Epub 2014 Jun 5.

8.

Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach.

Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, Zajicek J, Hobart J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S56-60. doi: 10.1016/j.jalz.2012.10.008.

PMID:
23391006
9.

Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory.

Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S10-20. doi: 10.1016/j.jalz.2012.08.006. Epub 2012 Dec 17.

PMID:
23253779
10.

Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods.

Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Feb;9(1 Suppl):S4-9. doi: 10.1016/j.jalz.2012.08.005. Epub 2012 Dec 17.

PMID:
23253777
11.

Disparities in routine breast cancer screening for Medicaid managed care members with a work-limiting disability.

Weir S, Posner HE, Zhang J, Jones WC, Willis G, Baxter JD, Clark RE.

Medicare Medicaid Res Rev. 2011 Nov 4;1(4). doi: 10.5600/mmrr.001.04.a02.

12.

Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer's disease patients.

Logue MW, Posner H, Green RC, Moline M, Cupples LA, Lunetta KL, Zou H, Hurt SW, Farrer LA, Decarli C; MIRAGE Study Group.

Alzheimers Dement. 2011 Sep;7(5):493-500. doi: 10.1016/j.jalz.2011.01.004. Epub 2011 Jul 1.

13.

Predictors of prenatal and postpartum care adequacy in a medicaid managed care population.

Weir S, Posner HE, Zhang J, Willis G, Baxter JD, Clark RE.

Womens Health Issues. 2011 Jul-Aug;21(4):277-85. doi: 10.1016/j.whi.2011.03.001. Epub 2011 May 12.

PMID:
21565526
14.

Assessment of cognition in early dementia.

Silverberg NB, Ryan LM, Carrillo MC, Sperling R, Petersen RC, Posner HB, Snyder PJ, Hilsabeck R, Gallagher M, Raber J, Rizzo A, Possin K, King J, Kaye J, Ott BR, Albert MS, Wagster MV, Schinka JA, Cullum CM, Farias ST, Balota D, Rao S, Loewenstein D, Budson AE, Brandt J, Manly JJ, Barnes L, Strutt A, Gollan TH, Ganguli M, Babcock D, Litvan I, Kramer JH, Ferman TJ.

Alzheimers Dement. 2011 May 1;7(3):e60-e76.

15.

The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.

Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, Hobart JC.

J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1363-8. doi: 10.1136/jnnp.2009.204008. Epub 2010 Sep 29.

PMID:
20881017
16.

Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size.

Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H.

Stroke. 2010 Jun;41(6):1213-21. doi: 10.1161/STROKEAHA.109.570077. Epub 2010 Apr 15.

17.

The long-term efficacy and tolerability of donepezil in patients with vascular dementia.

Wilkinson D, Róman G, Salloway S, Hecker J, Boundy K, Kumar D, Posner H, Schindler R.

Int J Geriatr Psychiatry. 2010 Mar;25(3):305-13. doi: 10.1002/gps.2340.

PMID:
19623601
18.

Scales as outcome measures for Alzheimer's disease.

Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y.

Alzheimers Dement. 2009 Jul;5(4):324-39. doi: 10.1016/j.jalz.2009.05.667.

PMID:
19560103
19.

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, Posner H, Chabriat HS.

Lancet Neurol. 2008 Apr;7(4):310-8. doi: 10.1016/S1474-4422(08)70046-2. Epub 2008 Feb 28.

PMID:
18296124
20.

Neuroradiological findings in vascular dementia.

Guermazi A, Miaux Y, Rovira-Cañellas A, Suhy J, Pauls J, Lopez R, Posner H.

Neuroradiology. 2007 Jan;49(1):1-22. Epub 2006 Nov 18. Review.

PMID:
17115204
21.

Dementia with lewy bodies.

Posner H, Chin S, Marder K.

Sci Aging Knowledge Environ. 2001 Oct 17;2001(3):dn3.

PMID:
14602963
22.

The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function.

Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R.

Neurology. 2002 Apr 23;58(8):1175-81.

PMID:
11971083
23.

Alternative medicine--the case of herbal remedies.

Posner H.

N Engl J Med. 1999 Feb 18;340(7):565; author reply 566. No abstract available. Erratum in: N Engl J Med 1999 Apr 1;340(13):1056.

PMID:
10026044
24.

An Ab initio study of the relationship between nitroarene mutagenicity and electron affinity.

Maynard AT, Pedersen LG, Posner HS, McKinney JD.

Mol Pharmacol. 1986 Jun;29(6):629-36.

PMID:
3520290
25.

Ascorbic acid and urinary oxalate.

Posner H.

Ann Intern Med. 1984 Oct;101(4):571-2. No abstract available.

PMID:
6476652
26.

Unambiguous reporting of the sex of human beings.

Posner HS.

Lancet. 1983 Jan 22;1(8317):175-6. No abstract available.

PMID:
6130210
27.
28.

Toxicity of polybrominated biphenyls (PBBs) in Domestic and laboratory animals.

Damstra T, Jurgelski W Jr, Posner HS, Vouk VB, Bernheim NJ, Guthrie J, Luster M, Falk HL.

Environ Health Perspect. 1982 Apr;44:175-88. Review.

30.

On the site of function of the Rieske iron-sulfur center in the chloroplast electron transport chain.

Malkin R, Posner HB.

Biochim Biophys Acta. 1978 Mar 13;501(3):552-4.

PMID:
204346
31.
32.

Indices of potential lead hazard.

Posner HS.

Environ Health Perspect. 1977 Aug;19:261-84. Review.

34.

Fetal toxicity and distribution of paraquat and diquat in mice and rats.

Bus JS, Preache MM, Cagen SZ, Posner HS, Eliason BC, Sharp CW, Gibson JE.

Toxicol Appl Pharmacol. 1975 Sep;33(3):450-60. No abstract available.

PMID:
1188943
35.

Biohazards of methanol in proposed new uses.

Posner HS.

J Toxicol Environ Health. 1975 Sep;1(1):153-71. Review. No abstract available.

PMID:
1102723
36.

Toxicity of metabolites produced by the "Alternaria".

Pero RW, Posner H, Blois M, Harvan D, Spalding JW.

Environ Health Perspect. 1973 Jun;4:87-94. No abstract available.

37.

Significance of cleft palate induced by chemicals in the rat and mouse.

Posner HS.

Food Cosmet Toxicol. 1972 Dec;10(6):839-55. No abstract available.

PMID:
4145257
38.

Correlation of paraquat toxicity with tissue concentrations and weight loss of the rat.

Sharp CW, Ottolenghi A, Posner HS.

Toxicol Appl Pharmacol. 1972 Jun;22(2):241-51. No abstract available.

PMID:
5048054
39.

Placental passage of 14C-dieldrin altered by gestational age and plasma proteins.

Eliason BC, Posner HS.

Am J Obstet Gynecol. 1971 Dec 1;111(7):925-9. No abstract available.

PMID:
4107382
41.

Reduced passage of carbon-14-dieldrin to the fetal rat by phenobarbital but not by eight other drugs or dieldrin.

Eliason BC, Posner HS.

Am J Obstet Gynecol. 1971 Aug 1;110(7):943-7. No abstract available.

PMID:
5558977
42.

Ammonium Ion and the Flowering of Lemna perpusilla.

Hillman WS, Posner HB.

Plant Physiol. 1971 Apr;47(4):586-7. No abstract available.

43.

Anomalies of the internal organs and diminished calcification of vertebrae in fetuses after benzhydrylpiperazine treatment of pregnant rats.

Posner HS, Darr A, Barrow MV.

Toxicol Appl Pharmacol. 1970 Jul;17(1):76-82. No abstract available.

PMID:
4393983
44.

Fetal edema from benzhydrylpiperazines as a possible cause of oral-facial malformations in rats.

Posner HS, Darr A.

Toxicol Appl Pharmacol. 1970 Jul;17(1):67-75. No abstract available.

PMID:
4393982
47.

Experimental alteration of the metabolism of chlorcyclizine and the incidence of cleft palate in rats.

Posner HS, Graves A, King CT, Wilk A.

J Pharmacol Exp Ther. 1967 Mar;155(3):494-505. No abstract available.

PMID:
4381513
48.

PHARMACOLOGICAL ACTIVITY OF 1-, 2-, AND 3-HYDROXYPROMAZINE AND 7-METHOXYCHLORPROMAZINE.

POSNER HS, HEARST E.

Int J Neuropharmacol. 1964 Dec;3:635-41. No abstract available.

PMID:
14347089
49.

THE BIPHASIC EFFECT OF PHENOTHIAZINES AND RESERPINE ON THE RELEASE OF EPINEPHRINE FROM ADRENOMEDULLARY GRANULES AND ITS DEPENDENCE ON PH.

WEIL-MALHERBE H, POSNER HS.

Biochem Pharmacol. 1964 May;13:685-90. No abstract available.

PMID:
14181271
50.

QUANTIFICATION AND PROBABLE STRUCTURE, IN HUMAN URINE, OF THE NONPHENOLIC AND PHENOLIC METABOLITES OF CHLORPROMAZINE.

POSNER HS, CULPAN R, LEVINE J.

J Pharmacol Exp Ther. 1963 Sep;141:377-91. No abstract available.

PMID:
14064202

Supplemental Content

Loading ...
Support Center